Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17389
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbou-Alfa, Ghassan K-
dc.contributor.authorBlanc, Jean-Frederic-
dc.contributor.authorMiles, Steven-
dc.contributor.authorGanten, Tom-
dc.contributor.authorTrojan, Jörg-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorLiem, Andre K-
dc.contributor.authorLipton, Lara-
dc.contributor.authorGupta, Charu-
dc.contributor.authorWu, Benjamin-
dc.contributor.authorBass, Michael-
dc.contributor.authorHollywood, Ellen-
dc.contributor.authorMa, Jennifer-
dc.contributor.authorBradley, Margaret-
dc.contributor.authorLitten, Jason-
dc.contributor.authorSaltz, Leonard B-
dc.date2017-06-07-
dc.date.accessioned2018-04-05T02:26:47Z-
dc.date.available2018-04-05T02:26:47Z-
dc.date.issued2017-07-
dc.identifier.citationThe oncologist 2017; 22(7): 780-e65-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17389-
dc.description.abstractTrebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC).In support of previously reported high Ang-2 levels' association with poor outcome in HCC for patients, trebananib treatment with lower baseline Ang-2 at study entry was associated with improved overall survival to 22 months and may suggest future studies to be performed within the context of low baseline Ang-2. Ang-1 and Ang-2 are angiopoietins thought to promote neovascularization via activation of the Tie-2 angiopoietin receptor. Trebananib sequesters Ang-1 and Ang-2, preventing interaction with the Tie-2 receptor. Trebananib plus sorafenib combination has acceptable toxicity. Elevated Ang-2 levels are associated with poor prognosis in hepatocellular carcinoma (HCC). Patients with HCC, Eastern Cooperative Oncology Group ≤2, and Childs-Pugh A received IV trebananib at 10 mg/kg or 15 mg/kg weekly plus sorafenib 400 mg orally twice daily. The study was planned for ≥78% progression-free survival (PFS) rate at 4 months relative to 62% for sorafenib historical control (power = 80% α = 0.20). Secondary endpoints included safety, tolerability, overall survival (OS), and multiple biomarkers, including serum Ang-2. Thirty patients were enrolled sequentially in each of the two nonrandomized cohorts. Demographics were comparable between the two arms and the historical controls. PFS rates at 4 months were 57% and 54% on the 10 mg/kg and 15 mg/kg trebananib cohorts, respectively. Median OS was 17 and 11 months, respectively. Grade 3 and above events noted in ≥10% of patients included fatigue, hypertension, diarrhea, liver failure, palmar-plantar erythrodysesthesia syndrome, dyspnea, and hypophosphatemia. One death was due to hepatic failure. Serum Ang-2 dichotomized at the median was associated with improved OS in both cohorts. There was no improvement in PFS rate at 4 months in either cohort, when compared with sorafenib historical control.-
dc.language.isoeng-
dc.titlePhase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.-
dc.typeJournal Article-
dc.identifier.journaltitleThe oncologist-
dc.identifier.affiliationMemorial Sloan Kettering Cancer Center, New York, New York, USA-
dc.identifier.affiliationWeill Cornell Medical College, New York, New York, USA-
dc.identifier.affiliationHôpital Saint-André, Bordeaux, France-
dc.identifier.affiliationCedars Sinai Hospital, Los Angeles, California, USA-
dc.identifier.affiliationUniversity of Heidelberg, Heidelberg, Germany-
dc.identifier.affiliationJohann Wolfgang Goethe University, Frankfurt, Germany-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationTranslational Oncology Research International, Long Beach, California, USA-
dc.identifier.affiliationWestern Hospital, Footscray, Victoria, Australia-
dc.identifier.affiliationAmgen Inc., ThoUSAnd Oaks, California, USA-
dc.identifier.doi10.1634/theoncologist.2017-0058-
dc.identifier.pubmedid28592620-
dc.type.austinClinical Trial, Phase II-
dc.type.austinJournal Article-
dc.type.austinRandomized Controlled Trial-
local.name.researcherCebon, Jonathan S
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.